De-escalation trials for FRCR 2A: when less treatment is the right answer
Some of the hardest FRCR 2A questions have an answer that does less: omit the chemotherapy, shorten the course, watch instead of irradiate. These questions are hard for a reason. The vignette usually carries one or two adverse-sounding features, a positive margin, a node, an intermediate score, so treating more feels safer. The exam is testing whether you know which trial showed that less was enough, and, just as often, which trial tried to do less and failed.
This guide sorts the de-escalation trials you are most likely to meet into the two groups that matter: the ones that succeeded, and the ones that did not. For each, it gives the population, the number to know and the exam trap.
Why the trial design matters
Most de-escalation trials are non-inferiority trials. They do not ask whether less treatment is better; they ask whether it is not unacceptably worse, judged against a margin set in advance. RTOG 1016, for example, set a non-inferiority margin of a hazard ratio of 1.45. Two consequences follow for the exam. First, "non-inferiority was not shown" is a negative result even when the absolute difference looks small, so the standard treatment stands. Second, a trial can show non-inferiority in one subgroup and not overall, which is exactly where the 2A sets its distractors.
De-escalation that worked
Breast: omitting chemotherapy on the recurrence score
TAILORx (Sparano et al, NEJM 2018) assessed the 21-gene recurrence score (Oncotype DX) in hormone-receptor-positive, HER2-negative, axillary-node-negative breast cancer. With a recurrence score of 11 to 25, endocrine therapy alone was non-inferior to chemoendocrine therapy for invasive disease-free survival. The detail that decides questions is age: in women 50 or younger there was some absolute benefit from chemotherapy as the score rose within 16 to 25. The trial supports omitting chemotherapy in most women older than 50 with a node-negative tumour and an intermediate score.
RxPONDER (Kalinsky et al, NEJM 2021) extended the question to one to three positive nodes and a recurrence score of 25 or lower, and found that menopausal status changed the answer. In postmenopausal women, 5-year invasive disease-free survival was 91.9% with endocrine therapy alone and 91.3% with chemoendocrine therapy (HR 1.02), with no chemotherapy benefit. In premenopausal women it was 89.0% against 93.9% (HR 0.60), a benefit from chemotherapy.
The trap: the same score means different things at 45 and at 62. Read the age, the menopausal status and the nodal status before the score.
Breast: omitting radiotherapy in older women
PRIME II (Kunkler et al, NEJM 2023) randomised women aged 65 or older with hormone-receptor-positive, node-negative, T1-2 (up to 3 cm) breast cancer, after breast-conserving surgery and on adjuvant endocrine therapy, to whole-breast irradiation or none. Ten-year local recurrence was 9.5% without radiotherapy and 0.9% with it, with no significant difference in distant recurrence, regional recurrence or overall survival. NICE NG101 (recommendation 1.13.7) says to consider not using radiotherapy for women aged 65 and over with T1N0, ER-positive, HER2-negative, grade 1 to 2 tumours and clear margins who are willing to take endocrine therapy for at least 5 years.
The trap: omission trades a real rise in local recurrence for no survival cost. It is an option to discuss, and it depends on the endocrine therapy being taken.
Colon: three months of CAPOX
The IDEA collaboration (Grothey et al, NEJM 2018) pooled six randomised trials of 3 against 6 months of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer, oxaliplatin being associated with cumulative neurotoxicity. Non-inferiority of 3 months was not confirmed overall (HR 1.07), and the answer splits by regimen and risk. It was shown for CAPOX (HR 0.95) but not for FOLFOX (HR 1.16). In T1-3 N1 cancers, 3 months was non-inferior, with 3-year disease-free survival of 83.1% against 83.3%. In T4, N2 or both, 6 months was superior (64.4% against 62.7%). NICE NG151 recommends CAPOX for 3 months for stage III colon cancer, with FOLFOX for 3 to 6 months or a single-agent fluoropyrimidine for 6 months if CAPOX is unsuitable.
The trap: "3 months of FOLFOX" is a distractor that looks like the IDEA answer and is not.
Prostate: observe rather than irradiate after prostatectomy
RADICALS-RT (Parker et al, Lancet 2020) randomised 1,396 men with at least one risk factor after radical prostatectomy (pT3 or pT4, Gleason 7 to 10, positive margins, or a preoperative PSA of at least 10 ng/mL) to adjuvant radiotherapy or observation with salvage radiotherapy for PSA biochemical progression. Five-year biochemical progression-free survival was 85% with adjuvant and 88% with salvage radiotherapy (HR 1.10, p=0.56), and adjuvant radiotherapy increased urinary morbidity. The trial concluded that observation with salvage radiotherapy for PSA progression should be the current standard.
The trap: the vignette lists every adverse feature RADICALS-RT recruited. They are the reason the man was eligible for the trial, not a reason to irradiate him now.
De-escalation that failed
HPV-positive oropharyngeal cancer: cetuximab is not the gentler option
Two trials tested replacing cisplatin with cetuximab in HPV-positive oropharyngeal cancer, hoping to keep control and reduce toxicity. Both failed.
De-ESCALaTE (Mehanna et al, Lancet 2019) treated low-risk p16-positive patients with 70 Gy in 35 fractions with cisplatin or cetuximab. Severe toxicity at 24 months did not differ between the arms, but 2-year overall survival was 97.5% with cisplatin against 89.4% with cetuximab, with more locoregional recurrence (12% against 3%) and distant metastasis (9% against 3%) on cetuximab.
RTOG 1016 (Gillison et al, Lancet 2019) used accelerated radiotherapy, 70 Gy in 35 fractions at six fractions a week, with the same comparison. Cetuximab did not meet non-inferiority: 5-year overall survival was 77.9% against 84.6% with cisplatin, and locoregional failure was 17.3% against 9.9%. Both trials concluded that cisplatin with radiotherapy remains the standard for patients who can have it.
The trap: the patient who "would rather avoid cisplatin" but is platinum-eligible. Cetuximab costs survival, and in De-ESCALaTE it bought no reduction in severe toxicity.
Early Hodgkin lymphoma: omitting radiotherapy after a negative PET
RAPID (Radford et al, NEJM 2015) gave three cycles of ABVD to patients with stage IA or IIA Hodgkin lymphoma and randomised those with a negative PET to involved-field radiotherapy or no further treatment. Three-year progression-free survival was 94.6% with radiotherapy and 90.8% without, and non-inferiority of omitting radiotherapy was not shown, although the prognosis was very good either way.
EORTC/LYSA/FIL H10 (André et al, JCO 2017) told the same story in stage I-II disease after two cycles of ABVD. The interim analysis stopped randomisation of early-PET-negative patients because omitting radiotherapy increased early relapse. In the final analysis of early-PET-negative favourable patients, 5-year progression-free survival was 99.0% with ABVD and involved-node radiotherapy against 87.1% with ABVD alone.
The trap: "PET-negative, so no radiotherapy" is a defensible individual choice, traded against late toxicity, not a trial-proven equivalent. Questions that ask for the evidence want you to know that non-inferiority was not shown.
The pattern, in one table
| Trial | Less treatment tested | Result for the exam |
|---|---|---|
| TAILORx | No chemotherapy, node-negative, RS 11 to 25 | Non-inferior; some benefit at 50 or younger |
| RxPONDER | No chemotherapy, 1 to 3 nodes, RS 25 or lower | No benefit postmenopausal; benefit premenopausal |
| PRIME II | No radiotherapy, 65 or older, low risk | More local recurrence, no survival difference |
| IDEA | 3 months, not 6 | CAPOX in T1-3 N1, yes; FOLFOX, no |
| RADICALS-RT | Observe and salvage, not adjuvant | No benefit from adjuvant radiotherapy |
| De-ESCALaTE, RTOG 1016 | Cetuximab, not cisplatin | Worse survival; cisplatin stays |
| RAPID, H10 | No radiotherapy after negative PET | Non-inferiority not shown |
When a 2A vignette offers you less treatment, ask two questions before you choose: which trial tested this exact population, and did it show that less was enough? The free question each day at frcrvault.com/free-question names its trial in the answer, so you can practise exactly that habit.
Weekly FRCR 2A revision email
The week's free questions and one teaching point, in one email. Unsubscribe any time. By subscribing you consent to marketing email from FRCR Vault (details in our privacy policy).
Educational content for FRCR 2A revision only, not medical advice. Clinical decisions belong with the treating team and current local protocols.